サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：診断用電気生理学カテーテルの世界市場-2023年～2030年
市場調査レポート
商品コード
1345411

診断用電気生理学カテーテルの世界市場-2023年～2030年

Global Diagnostic Electrophysiology Catheters Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
診断用電気生理学カテーテルの世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

診断用電気生理学カテーテルの世界市場は、2022年に16億米ドルに達し、2023-2030年の予測期間中にCAGR 8.1%で成長し、2030年には29億米ドルに達すると予測されています。

心臓病学分野の診断用電気生理学カテーテルは、様々な心臓不整脈やその他の電気生理学的異常を特定・理解する上で極めて重要な専門医療機器です。これらのカテーテルは心臓の異常な電気的活動を評価・診断するために使用されます。カテーテルは血管を通して心臓に導入され、心臓の電気信号のリアルタイムデータとマッピングを提供します。

診断用電気生理学カテーテルは、特定の用途向けに設計・構成されています。カテーテルには複数の電極があり、心臓のさまざまな部位から電気信号を記録することができます。これにより、心臓専門医や電気生理学者は不整脈の発生源を突き止め、心臓機能全体を評価することができます。

さらに、診断用電気生理学カテーテルは、透視検査や3Dマッピングシステムなどの高度な画像技術とともに使用されることが多く、可視化を強化してカテーテル留置の精度を向上させています。さらに、心臓不整脈の有病率の上昇、電気生理学マッピングシステムの採用増加、診断用電気生理学カテーテルの技術革新は、予測期間中に市場を牽引すると予想される要因です。

ダイナミクス

主要企業による製品上市の増加が市場成長を牽引すると予測

2022年10月13日、Johnson &Johnson MedTechの子会社であるBiosense Webster社からHELIOSTAR Balloon Ablation Catheterが発売され、欧州市場で入手可能な初の高周波バルーンアブレーションカテーテルとなっています。このカテーテルは、心房のカテーテルベースの心臓電気生理学的マッピングと、互換性のあるマルチチャンネルRFジェネレーターと併用する心臓アブレーション用に特別に設計されています。このカテーテルの特徴は、10個の金メッキ灌流電極を備えていることで、解剖学的位置や組織の厚さに応じて、出力をカスタマイズすることができます。HELIOSTARカテーテルは、円周方向アブレーションとセグメントアブレーションの両方が可能であるため、個々の肺静脈（PV）アブレーションに対応できます。さらに、各電極への電力供給を独立して制御できるため、柔軟性と有効性が向上します。

同様に、2023年7月24日、ジョンソン・エンド・ジョンソンMedTech傘下の重要なプレーヤーであるバイオセンス・ウェブスター社によって、TRUErefテクノロジーを搭載したOPTRELLマッピングカテーテルが米国の心臓不整脈治療市場に導入されました。この診断用カテーテルは、CARTO 3システムとともに開発されたもので、小型電極を高密度に配置した固定アレイ構成を特徴としています。この構成は、持続性心房細動（AFib）、AFibアブレーションのやり直し、心房頻拍、心室頻拍などの複雑な不整脈症例における正確な電気生理学的マッピングに理想的です。

バイオセンス・ウェブスター社が最近発表したHELIOSTARおよびOPTRELLカテーテルは、心臓電気生理学の課題に対処するための革新的技術の重要性を強調しています。これらの先進的なツールは、心臓マッピングとアブレーションに対する精密で効率的、かつカスタマイズ可能なアプローチに対するニーズの高まりに応えるものです。バイオセンス・ウェブスターは、患者の予後を向上させ、手技を簡素化し、不整脈治療の全体的な状況を改善することに全力を注いでおり、このような新製品の発表にもそれが表れています。

診断用電気生理学カテーテルの技術革新が市場成長を牽引する見込み

2022年5月4日、Siemens Healthineers社は、心臓内エコー（ICE）技術を大きく進歩させたAcuNav Volume 4D ICEカテーテルを米国で発表しました。このカテーテルの遠位先端部は革新的で、操作性と重要な構造の可視化を向上させています。この開発により、医師はより解剖学的構造に近づくことができ、心臓の構造的処置においてより良い治療を提供することができます。

この最新の進歩は、経食道エコー（TEE）や全身麻酔のような禁忌のためにこれまでそのような手技を受けることができなかった患者や、三尖弁逆流がある患者にとって特に有益です。このカテーテルのデザインはまた、病院の効率を高め、カテ室のターンアラウンドタイムを短縮し、全身麻酔の必要性をなくすことを目指しています。画像診断技術のリーダーとしてのシーメンス・ヘルスイニアースの地位は、AcuNav Volume ICEカテーテルの精度と心臓構造手術における治療成績の改善によってさらに強化されます。

したがって、AcuNav Volume ICE Catheterのような先進的なカテーテルが利用可能になることで、診断用電気生理学カテーテル市場はさらなる成長を遂げる可能性があり、これは患者、医療従事者、業界全体に利益をもたらすと思われます。したがって、上記のような要因から、予測期間中、市場は牽引役となることが期待されます。

診断用電気生理学カテーテル導入のための高コストが市場成長の妨げになる見込み

診断用電気生理学カテーテルとそれに必要な機器に関連する高額な費用は、その採用を妨げる可能性があります。そのようなカテーテルの1つである電気生理カテーテルBIOSENSE WEBSTER：D7TCJ8L162RTは、サイズ7Fr、挿入長115cm、Jカーブタイプ、4電極、先端電極8mm、間隔1-6-2mmで、診断介入用の有望な医療ツールとなっています。しかし、その可能性にもかかわらず、予測期間中、市場の成長は大きな障害に直面する可能性があります。1台当たり600.97米ドルというコストは、予算が限られているヘルスケア施設にとって大きな経済的障壁となる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 主要企業による製品上市の増加
      • 診断用電気生理学カテーテルにおける技術革新
    • 抑制要因
      • 診断用電気生理学カテーテル導入のための高コスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • 特許分析
  • ロシア・ウクライナ紛争分析
  • DMIの見解

第6章 COVID-19分析

第7章 タイプ別

  • RFアブレーションカテーテル
  • 代替エネルギーアブレーションカテーテル
    • 冷凍アブレーション
    • レーザーアブレーション
    • 超音波
  • 高密度マッピングカテーテル
  • ICEカテーテル

第8章 技術別

  • 固定カーブ型診断カテーテル
  • 可動型診断カテーテル

第9章 エンドユーザー別

  • 病院
  • 外来手術センター
  • 心臓カテーテル検査室
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Abbott Laboratories
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Boston Scientific Corporation
  • Johnson and Johnson（Biosense Webster）
  • Integer Holdings Corporation
  • Medtronic
  • Lepu Medical Technology（Beijing）Co.,Ltd.
  • Access Point Technologies EP
  • BIOTRONIK
  • CathRx Ltd.
  • Siemens Healthineers

第13章 付録

目次
Product Code: MD1323

Overview

Global Diagnostic Electrophysiology Catheters Market reached US$ 1.6 billion in 2022 and is expected to reach US$ 2.9 billion by 2030, growing with a CAGR of 8.1% during the forecast period 2023-2030.

Diagnostic Electrophysiology Catheters in the field of cardiology are specialized medical devices that are crucial in identifying and understanding various cardiac arrhythmias and other electrophysiological abnormalities. These catheters are used to assess and diagnose abnormal electrical activity in the heart. They are introduced into the heart through blood vessels and provide real-time data and mapping of the heart's electrical signals.

Diagnostic electrophysiology catheters are designed and configured for specific applications. They have multiple electrodes capable of recording electrical signals from different regions of the heart. This helps cardiologists and electrophysiologists to pinpoint the source of arrhythmias and evaluate the overall heart function.

Moreover, diagnostic electrophysiology catheters are often used in conjunction with advanced imaging technologies, such as fluoroscopy and 3D mapping systems, to enhance visualization and improve the precision of catheter placement. Furthermore, the rising prevalence of cardiac arrhythmias, increasing adoption of electrophysiology mapping systems, and innovations in diagnostic electrophysiology catheters are the factors expected to drive the market over the forecast period.

Dynamics

The Increasing Product Launches by the Key Market Players is Expected to Drive the Market Growth

On October 13, 2022, the HELIOSTAR Balloon Ablation Catheter was released by Biosense Webster, a subsidiary of Johnson & Johnson MedTech, and is the first radiofrequency balloon ablation catheter available in the European market. It is specifically designed for catheter-based cardiac electrophysiological mapping of the atria and cardiac ablation when used alongside a compatible multi-channel RF generator. Its unique feature is the presence of ten gold-plated, irrigated electrodes, which can be customized to deliver power based on anatomical location and tissue thickness. The HELIOSTAR catheter is capable of both circumferential and segmental ablation, which allows for personalized pulmonary vein (PV) ablation. Additionally, the ability to control power delivery to each electrode independently enhances its flexibility and efficacy.

Similarly, on July 24, 2023, the OPTRELL Mapping Catheter with TRUEref Technology was introduced to the cardiac arrhythmia treatment market in the U.S. by Biosense Webster, Inc., a significant player under Johnson & Johnson MedTech. This diagnostic catheter, developed alongside the CARTO 3 System, features a fixed array configuration with a high-density arrangement of small electrodes. This configuration is ideal for precise electrophysiological mapping in complex cardiac arrhythmia cases, including persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia.

The recent release of the HELIOSTAR and OPTRELL catheters by Biosense Webster highlights the importance of innovative technologies in addressing challenges in cardiac electrophysiology. These advanced tools cater to the increasing need for precise, efficient, and customizable approaches to cardiac mapping and ablation. Biosense Webster's dedication to enhancing patient outcomes, simplifying procedures, and improving the overall landscape of arrhythmia treatment is evident in these new product launches.

Innovations in Diagnostic Electrophysiology Catheters are Expected to Drive Market Growth

On May 4, 2022, Siemens Healthineers introduced the AcuNav Volume 4D ICE Catheter, which is a significant advancement in intracardiac echocardiography (ICE) technology in the United States. The catheter's distal tip is innovative, improving maneuverability and visualization of critical structures. This development enables physicians to get closer to the anatomy and provide better care during structural heart procedures.

The latest advancement is especially beneficial for patients who were previously unable to undergo such procedures due to contraindications like transesophageal echo (TEE) or general anesthesia, as well as those with tricuspid regurgitation. The catheter's design also aims to enhance hospital efficiency, reduce cath lab turnaround time, and eliminate the need for general anesthesia. Siemens Healthineers' position as a leader in diagnostic imaging technology is further strengthened by the AcuNav Volume ICE Catheter's precision and improved outcomes in structural heart procedures.

Therefore, the diagnostic electrophysiology catheters market could experience further growth due to the availability of advanced catheters like the AcuNav Volume ICE Catheter, which would benefit patients, healthcare providers, and the industry as a whole. Hence, owing to the above factors, the market is expected to drive the market over the forecast period.

High Cost for Diagnostic Electrophysiology Catheters Adoption is Expected to Hamper the Market Growth

The high expenses associated with diagnostic electrophysiology catheters and their required equipment can hinder their adoption. One such catheter, the Electrophysiology Catheter BIOSENSE WEBSTER: D7TCJ8L162RT, has a size of 7 Fr, an insertion length of 115 cm, a J-curve type, 4 electrodes, an 8 mm tip electrode, and a spacing of 1-6-2 mm, making it a promising medical tool for diagnostic interventions. However, despite its potential, the market's growth may face significant obstacles during the projected forecast period. The cost of $600.97 per unit may create a significant economic barrier for healthcare facilities with limited budgets.

Segment Analysis

The global diagnostic electrophysiology catheter market is segmented based on type, technology, end user and region.

The RF Ablation Catheters from the Type Segment Accounted for Approximately 38.9% of the Diagnostic Electrophysiology Catheters Market Share

Radiofrequency (RF) Ablation Catheters are advanced medical devices used in different procedures to treat conditions such as cardiac arrhythmias and specific tumors. These catheters use controlled radiofrequency energy to destroy abnormal tissue without requiring open surgery. They offer advantages such as enhanced accuracy in targeting specific tissue, decreased patient discomfort, shorter recovery periods, and reduced risks compared to traditional surgical methods.

For instance, Medtronic, The 7 French RF Marinr Multi-Curve Steerable Catheter is a specialized medical tool used in minimally invasive interventional cardiology procedures. It has a diameter of 7 French and is designed to navigate the cardiovascular system with ease, thanks to its multiple pre-shaped curves that enhance maneuverability.

This catheter is primarily intended for radiofrequency ablation, which is used to treat cardiac arrhythmias by delivering controlled energy to selectively destroy irregular heart tissue. The catheter's steerable capabilities enable precise navigation through complex pathways, which improves control for accessing challenging anatomical sites and performing delicate procedures effectively.

When combined with RF ablation, this catheter enhances patient outcomes, reduces procedure times, and increases comfort compared to traditional surgical methods. To ensure optimal use and patient care, healthcare professionals must receive proper training in using this catheter.

Furthermore, the RF Ablation catheter market is driven by factors such as the increasing prevalence of cardiac arrhythmias, rising demand for minimally invasive treatment options, and advancements in catheter technology.

For instance, on March 15, 2023, received CE (Conformite Europeenne) Mark for the Affera Mapping and Ablation System, which includes the Sphere-9 Catheter and the Affera Prism-1 Mapping Software. Together, the full system creates a new paradigm in electrophysiology through the unique integration of the Sphere-9 pulsed field ablation (PFA), radiofrequency (RF), and high density (HD) mapping catheter, which maps and ablates atrial arrhythmias (fast, abnormal heart rhythms) and provides real-time feedback through its intuitive mapping and navigation software.

Moreover, Atrial fibrillation (AFib) is the most common atrial arrhythmia, and nearly 60 million people are affected worldwide and five million patients will be added every year by 2030. Atrial arrhythmias, such as AFib, are associated with serious complications including heart failure, stroke, and increased risk of death.

Additionally, on May 15, 2023, Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announced that data from the Q-FFICIENCY study was published in JACC: Clinical Electrophysiology. The study evaluated the safety and 12-month effectiveness of the QDOT MICRO Catheter in paroxysmal atrial fibrillation (AFib) ablation using the very high-power short-duration (QMODE+) mode combined with conventional-power temperature-controlled (QMODE) mode.

The Biosense Webster QDOT MICRO Catheter is a next-generation RF ablation catheter that was granted CE Mark in 2020 and FDA approval in 2022. This catheter is designed to provide improved procedural efficiency and ablation efficiency for treating atrial fibrillation (AF). It is the world's first very high-power, short-duration ablation catheter.

Nevertheless, the market growth can be impeded by challenges like limited awareness among patients and healthcare professionals, high upfront costs of equipment, and the requirement for specialized training to operate the devices effectively. Therefore, these obstacles require continuous medical education, cost-effective solutions, and ongoing research to demonstrate the safety and efficacy of RF ablation procedures.

Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share in 2022, Owing to the Increasing FDA Approvals, Growing Product Launches, and Presence of Key Market Players in the Region

North America region is expected to hold the largest market share over the forecast period owing to the increasing FDA approvals, growing product launches, and presence of key market players in the region. For instance, on February 2, 2023, Abbott announced two approvals as part of its growing suite of electrophysiology products in the global market. The company's TactiFlex Ablation Catheter, Sensor Enabled, the world's only ablation catheter with a flexible tip and contact force sensing, received CE Mark for treating people with abnormal heart rhythms like atrial fibrillation (AFib). Abbott's FlexAbility Ablation Catheter, Sensor Enabled also recently secured an expanded indication for treating patients with a complex heart condition by the U.S. Food and Drug Administration (FDA).

Similarly, on February 2, 2023, MicroPort EP obtained approval from the Food and Drug Administration in the United States of America (U.S.) for its independently researched and developed EasyFinder Fixed Curve Diagnostic Catheter. This product is the first mapping catheter from MicroPort EP to get FDA approval.

Therefore, the approval of more diagnostic electrophysiology catheters by the FDA in the region has a significant positive impact on the market. It encourages innovation, improves patient care, increases clinical confidence, attracts investments, and establishes the region as a leader in the field. Moreover, there is potential to revolutionize the diagnosis and treatment of heart rhythm disorders, leading to benefits for both healthcare providers and patients. Thus, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the diagnostic electrophysiology catheters market include: Abbott Laboratories, Boston Scientific Corporation, Johnson and Johnson (Biosense Webster), Integer Holdings Corporation, Medtronic, Lepu Medical Technology (Beijing)Co., Ltd., Access Point Technologies EP., BIOTRONIK, CathRx Ltd. and Siemens Healthineers among others.

COVID-19 Impact Analysis

COVID-19 has significantly impacted the diagnostic electrophysiology catheters market. Due to the pandemic's peak, hospitals had to delay or cancel elective procedures, including diagnostic electrophysiology procedures. As a result, the usage of diagnostic electrophysiology catheters decreased, and healthcare resources were redirected toward managing COVID-19 cases.

Patients with non-urgent cardiac conditions often postpone routine check-ups and diagnostic tests due to their fear of exposure to the virus. This decrease in patient visits resulted in less demand for diagnostic electrophysiology catheters. The focus of hospitals and medical facilities shifted to managing COVID-19 cases, which meant that essential and life-threatening procedures took priority. Elective diagnostic procedures like electrophysiology studies using catheters were deprioritized during this time. The pandemic also had an impact on research and development activities, with potential delays to the introduction of new and innovative diagnostic electrophysiology catheter technologies to the market.

With the improving situation of the pandemic and the stabilization of healthcare systems, the market for Diagnostic Electrophysiology Catheters is anticipated to slowly bounce back. The demand for precise diagnosis and treatment of heart conditions is still present, and the market is expected to recover as elective surgeries resume, patients regain trust, and healthcare resources are redirected toward non-COVID-19-related services.

By Type

  • RF Ablation Catheters
  • Alternative Energy Ablation Catheters
    • Cryoablation
    • Laser Ablation
    • Ultrasound
  • High-Density Mapping Catheters
  • ICE Catheters

By Technology

  • Fixed Curve Diagnostics Catheters
  • Steerable Diagnostics Catheters

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiac Catheterization Laboratories
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On July 24, 2023, Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announced the U.S. launch of the OPTRELL Mapping Catheter with TRUEref Technology powered by the CARTO 3 System. The OPTRELL Mapping Catheter is a high-density diagnostic catheter, with small electrodes arranged in a fixed array formation to provide high-definition electrophysiological mapping of complex cardiac arrhythmia cases like persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia.
  • On September 06, 2022, Royal Philips, a global leader in health technology, announced that Baptist Health's Miami Cardiac & Vascular Institute (Florida, U.S.) successfully started treating patients with Verisight Pro, Philips' real-time 3D Intracardiac Echocardiography (ICE) catheter, during minimally-invasive image-guided procedures for structural heart disease. Offering superior 2D and 3D live imaging, VeriSight Pro allows interventionalists to navigate procedures with ease, provide superior care, and optimize the performance of the interventional suite to benefit more heart patients.

DataM Intelligence Opinion:

According to DataM Intelligence, the diagnostic electrophysiology catheter market is being driven by new and innovative products, such as the HELIOSTAR Balloon Ablation Catheter and AcuNav Volume 4D ICE Catheter. These advancements demonstrate the industry's dedication to improving cardiac electrophysiology tools.

However, the COVID-19 pandemic has created challenges for the market, including delays in procedures and fewer patient visits. Despite these setbacks, the market is expected to recover due to the importance of accurate diagnosis, ongoing advancements, and North America's strong presence in the industry, thanks to FDA approvals. Collaboration between medical professionals, researchers, and manufacturers will be crucial in shaping the future of the market, improving patient care, and making the industry more adaptable. This will lead to sustained growth and a positive global impact.

Why Purchase the Report?

  • To visualize the global diagnostic electrophysiology catheters market segmentation based on type, technology, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of diagnostic electrophysiology catheters market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global diagnostic electrophysiology catheters market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Technology
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Increasing Product Launches by the Key Market Players
      • 4.1.1.2. Innovations in Diagnostic Electrophysiology Catheters
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost for Diagnostic Electrophysiology Catheters Adoption
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Patent Analysis
  • 5.7. Russian-Ukraine Conflict Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. RF Ablation Catheters*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Alternative Energy Ablation Catheters
    • 7.3.1. Cryoablation
    • 7.3.2. Laser Ablation
    • 7.3.3. Ultrasound
  • 7.4. High-Density Mapping Catheters
  • 7.5. ICE Catheters

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Fixed Curve Diagnostics Catheters*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Steerable Diagnostics Catheters

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Cardiac Catheterization Laboratories
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Abbott Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Boston Scientific Corporation
  • 12.3. Johnson and Johnson (Biosense Webster)
  • 12.4. Integer Holdings Corporation
  • 12.5. Medtronic
  • 12.6. Lepu Medical Technology (Beijing)Co.,Ltd.
  • 12.7. Access Point Technologies EP
  • 12.8. BIOTRONIK
  • 12.9. CathRx Ltd.
  • 12.10. Siemens Healthineers

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us